By Josh White
Date: Thursday 16 Mar 2023
(Sharecast News) - Specialist contract research organisation hVIVO has successfully manufactured its Omicron human challenge agent, it announced on Thursday.
By Josh White
Date: Monday 22 Aug 2022
(Sharecast News) - Specialist contract research organisation Open Orphan announced on Monday that its subsidiary hVIVO has signed a £10.4m contract with an existing, unnamed top-five global pharmaceutical client to manufacture a new batch of H1N1 flu challenge virus, and to conduct a human challenge trial to test the client's antiviral product.
By Josh White
Date: Tuesday 14 Jun 2022
(Sharecast News) - Contract research organisation Open Orphan announced on Tuesday that iits subsidiary hVIVO has signed a £7.2m contract with an existing global pharmaceutical company to test its orally-administered antiviral product using its human challenge study model for respiratory syncytial virus (RSV).
Currency | UK Pounds |
Share Price | 27.50p |
Change Today | 0.000p |
% Change | 0.00 % |
52 Week High | 30.50 |
52 Week Low | 14.25 |
Volume | 0 |
Shares Issued | 680.37m |
Market Cap | £187.10m |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 3 |
Buy | 3 |
Neutral | 0 |
Sell | 0 |
Strong Sell | 0 |
Total | 6 |
Latest | Previous | |
---|---|---|
Final | Special | |
Ex-Div | 18-Apr-24 | 04-May-23 |
Paid | 20-May-24 | 09-Jun-23 |
Amount | 0.20p | 0.45p |
You are here: research